Stimulation of regulatory T cells with Lactococcus lactis expressing enterotoxigenic E. coli colonization factor antigen 1 retains salivary flow in a genetic model of Sjögren's syndrome

• Published in: Arthritis research & therapy Vol. 23; no. 1; p. 99
• Main Authors: Akgul, Ali, Maddaloni, Massimo, Jun, Sang Mu, Nelson, Andrew S, Odreman, Vanessa Aguilera, Hoffman, Carol, Bhagyaraj, Ella, Voigt, Alexandria, Abbott, Jeffrey R, Nguyen, Cuong Q, Pascual, David W
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 06.04.2021; BioMed Central; BMC
• Subjects: Animals; Antigen 1, IL-10, TGF-β; Antigens; Arthritis; Autoimmune diseases; Biological products; Care and treatment; Colonization factor; Cytokines; Diabetes; Disease; Disease Models, Animal; E coli; Enterotoxigenic Escherichia coli; Escherichia coli; Fimbriae Proteins; Genetic aspects; Health aspects; Histology; Humans; Laboratory animals; Lactococcus; Lactococcus lactis; Lactococcus lactis - genetics; Lymphocytes; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Models, Genetic; Regulatory T cells; Salivary glands; Sjogren's syndrome; Sjogren's Syndrome - genetics; Suppressor cells; T-Lymphocytes, Regulatory; United States; United States > US; Colonization factor; Lactococcus lactis; Antigen 1, IL-10, TGF-β; Sjogren’s syndrome; Regulatory T cells
• ISSN: 1478-6362; 1478-6354; 1478-6362
• DOI: 10.1186/s13075-021-02475-1

Sjögren's syndrome (SjS), one of the most common autoimmune diseases, impacts millions of people annually. SjS results from autoimmune attack on exocrine (salivary and lacrimal) glands, and women are nine times more likely to be affected than men. To date, no vaccine or therapeutic exists to treat SjS, and patients must rely on lifelong therapies to alleviate symptoms. Oral treatment with the adhesin from enterotoxigenic Escherichia coli colonization factor antigen I (CFA/I) fimbriae protects against several autoimmune diseases in an antigen (Ag)-independent manner. Lactococcus lactis, which was recently adapted to express CFA/I fimbriae (LL-CFA/I), effectively suppresses inflammation by the induction of infectious tolerance via Ag-specific regulatory T cells (Tregs), that produce IL-10 and TGF-β. To test the hypothesis that CFA/I fimbriae can offset the development of inflammatory T cells via Treg induction, oral treatments with LL-CFA/I were performed on the spontaneous, genetically defined model for SjS, C57BL/6.NOD-Aec1Aec2 mice to maintain salivary flow. Six-week (wk)-old C57BL/6.NOD-Aec1Aec2 mice were orally dosed with LL-CFA/I and treated every 3 wks; control groups were given L. lactis vector or PBS. LL-CFA/I-treated mice retained salivary flow up to 28 wks of age and showed significantly reduced incidence of inflammatory infiltration into the submandibular and lacrimal glands relative to PBS-treated mice. A significant increase in Foxp3 and IL-10- and TGF-β-producing Tregs was observed. Moreover, LL-CFA/I significantly reduced the expression of proinflammatory cytokines, IL-6, IL-17, GM-CSF, and IFN-γ. Adoptive transfer of CD4 T cells from LL-CFA/I-treated, not LL vector-treated mice, restored salivary flow in diseased SjS mice. These data demonstrate that oral LL-CFA/I reduce or halts SjS progression, and these studies will provide the basis for future testing in SjS patients.